Disease Areas

This MC Sciences first-in-class therapeutics target several major disease areas with high unmet need in dermatology, respiratory, gastrointestinal conditions, fibrotic diseases, chronic inflammation disorders and neuroinflammation.

The primary therapeutic focus of MC is on major diseases such as chronic urticaria, systemic mastocytosis, COPD, asthma, food allergy, pulmonary and liver fibrosis, and chronic inflammation disorders.

In addition to major disease areas, MC Sciences therapeutics holds the promise for a significant better treatment for “hidden” chronic inflammatory disorders, such as MCAS, chronic lyme, fibromyalgia, IBS, POTS / EDS often driven by dysfunctional and chronically activated mast cells.

Prof Gerhard J. Molderings, co-founder and CMO of MC Sciences: “Diseases driven by dysfunctional or chronically activated mast cells remain a high unmet medical need in several disease areas including a high number of patients with “hidden” chronic inflammatory disorders. I am very confident and pleased that my lifetime work is transforming to finally bringing novel therapeutics to so many millions of patients that deserve a better life and create a positive difference for humanity.”